Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRA_1802 is a small molecule compound belonging to the class of phenylbenzimidazoles, specifically described as 2-{5-[amino(iminium)methyl]-1H-benzimidazol-2-yl}-4-fluorobenzenolate. It has the chemical formula C14H11FN4O. The compound is referenced in structural and chemical databases but does not have an established clinical use or detailed pharmacological profile in humans. Its mechanism of action and therapeutic indications are not well characterized in public sources, though it has been studied for its interaction with drug transporters such as MATE1 (Multidrug And Toxin Extrusion protein 1)[1][2][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRA_1802.